Introduction: Global healthcare AI company, Huma Therapeutics Limited, has introduced the Huma Cloud Platform, following a successful Series D funding round of $80 million. This technology ecosystem is designed to support various companies’ digital health initiatives and assist them in scaling their projects.

Why It's Notable: The Huma Cloud Platform allows for no-code configuration of regulated disease management tools applicable to any therapeutic area. In 2023, Huma became the first and only configurable, disease-agnostic platform certified as FDA Class II, EU MDR Class IIb, and Saudi FDA Class C. Initially developed for Huma’s own products, the platform is now available to customers with a Software Development Kit (SDK) to speed up development. With a robust regulatory framework, Huma aims to drastically reduce the time required to develop and launch digital health projects from years to just days.

The platform boasts numerous features to enhance digital-first care and research. It includes a library of pre-built modules, device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, and a marketplace. Additionally, AI tools are incorporated to automate significant portions of app development, and partnerships with Google and other collaborators enable the platform to support a larger number of patients simultaneously.

Point of View: Expanding Opportunities and Enhancing Healthcare Efficiency

The Huma Cloud Platform’s launch presents significant opportunities for various stakeholders in the digital health ecosystem, including start-ups, pharma, and healthcare providers. Start-ups can focus on their projects and business success without the burden of regulatory and technological scaling concerns. The platform also promises to improve healthcare efficiency through advanced automation enabled by generative AI models, allowing developers to create digital health tools that, for example, manage chronic diseases with fewer staff or ensure treatment adherence through real-time monitoring. It is proposed that through scaling digital health, it will become more affordable and consistent, helping to transition care from reactive to proactive on a greater scale.

For the pharmaceutical industry, the Huma Cloud Platform could revolutionize digital health development and adoption. Huma has collaborated with over half of the top 20 pharma companies, including major partners like AstraZeneca and Leaps by Bayer, who participated in the recent funding round. Investors are excited about the platform’s potential to streamline the process of bringing digital medicine, companion apps, and data collection capabilities to patients throughout drug development and commercialization. The Huma platform promises substantial cost-saving opportunities by reducing the time and effort needed to develop and scale digital health solutions in pharma.

After a year of internal restructuring, focused on efficiency savings and enhancing profitability, Huma’s future appears promising. This launch represents a shift in Huma’s business model, towards a consumption based model, which company CEO Vahdat reports will be more scalable and have higher margins for the company. The Huma Cloud Platform opens up a new revenue stream for the company, and Vahdat hopes to achieve profitability by the end of the year, with expected revenue from third parties leveraging the platform to outpace in-house projects. In an era of change for digital health, adapting is key to survival, and with strong industry backing, it will be exciting to see how Huma’s ‘Shopify for digital health’ approach will impact the next phase of digital health transformation. 

See original story here.